Evommune, Inc. (NYSE:EVMN) Receives Average Rating of “Buy” from Brokerages

Evommune, Inc. (NYSE:EVMN) has received a consensus recommendation of “Buy” from the fourteen ratings firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, nine have issued a buy rating and three have given a strong buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $49.25.

A number of equities analysts have recently commented on EVMN shares. Royal Bank Of Canada reissued an “outperform” rating and set a $48.00 price target on shares of Evommune in a report on Friday, April 10th. Weiss Ratings started coverage on Evommune in a report on Tuesday, February 3rd. They set a “sell (e)” rating for the company. Oppenheimer began coverage on Evommune in a report on Tuesday, April 7th. They set an “outperform” rating and a $50.00 price target for the company. Evercore restated an “outperform” rating and set a $55.00 price objective on shares of Evommune in a research report on Tuesday, February 10th. Finally, Wall Street Zen upgraded Evommune from a “sell” rating to a “hold” rating in a research report on Sunday, May 10th.

Evommune Price Performance

Evommune stock opened at $23.01 on Monday. Evommune has a 52 week low of $13.89 and a 52 week high of $33.20. The firm has a market cap of $828.86 million and a PE ratio of -2.42. The stock’s fifty day simple moving average is $24.14.

Evommune (NYSE:EVMN) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.64) EPS for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.19. As a group, research analysts anticipate that Evommune will post -2.83 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in EVMN. Strs Ohio acquired a new position in shares of Evommune during the first quarter valued at about $41,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Evommune during the fourth quarter valued at about $34,000. The Manufacturers Life Insurance Company acquired a new position in shares of Evommune during the fourth quarter valued at about $179,000. XTX Topco Ltd purchased a new stake in shares of Evommune in the fourth quarter worth approximately $321,000. Finally, Oxford Asset Management LLP purchased a new stake in shares of Evommune in the fourth quarter worth approximately $335,000.

About Evommune

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.